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Group B Streptococcus (GBS) is a common cause 
of sepsis and meningitis in human newborns 
(Dermer et al., 2004). The GBS capsular poly-
saccharide (CPS) is a critical virulence factor 
containing a terminal 2-3–linked N-acetyl-
neuraminic acid, identical to the most common 
sialic acid (Sia) capping many surface glycans on 
all human cells (Varki, 2007). To date, structures 
of nine antigenically distinct GBS CPS have been 
described (serotypes Ia, Ib, and II-VIII), each 
composed of unique arrangements of galactose, 
glucose, and/or N-acetylglucosamine but invari-
antly possessing Sia on the branching terminus of 
the repeating unit (Paoletti and Kasper, 2003). By 
increasing affinity of serum factor H for C3b and 
accelerating intrinsic decay of the C3 convertase,   
host Sia counterregulates complement activa-
tion (Pangburn, 2000). Likewise, by decorating its 
own surface with Sia, GBS creates a nonactivat-
ing environment restricting alternative comple-
ment deposition (Marques et al., 1992), impairing 
opsonophagocytic clearance and promoting dis-
ease progression (Wessels et al., 1989).
The Sia-recognizing Ig superfamily lectins 
(Siglecs) are a type-I transmembrane protein fam-
ily, consisting of an N-terminal Sia-binding V-set 
domain and a variable number of extracellular   
C2-set domains (Varki and Angata, 2006; Crocker   
et al., 2007; Varki, 2007). Human CD33-related 
Siglecs (hCD33rSiglecs), comprising Siglecs 3, 
5–11, XII, 14, and 16, are a rapidly evolving   
subgroup of Siglecs predominantly expressed   
on leukocytes (Crocker et al., 2007). The most 
prominent  Siglecs  on  human  monocyte/
macrophages, neutrophils, and dendritic cells are 
Siglec-5 (hSiglec-5) and Siglec-9 (hSiglec-9), 
each of which contains two intracellular tyro-
sine-based signaling motifs (Crocker et al., 2007). 
The membrane-proximal motif (LHYASL) con-
forms to the canonical immunoreceptor tyro-
sine–based inhibitory motif (I/L/V)xYxx(L/V),   
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Group B Streptococcus (GBS) is a leading cause of invasive bacterial infections in human 
newborns. A key GBS virulence factor is its capsular polysaccharide (CPS), displaying termi-
nal sialic acid (Sia) residues which block deposition and activation of complement on the 
bacterial surface. We recently demonstrated that GBS Sia can bind human CD33-related 
Sia-recognizing immunoglobulin (Ig) superfamily lectins (hCD33rSiglecs), a family of inhibi-
tory receptors expressed on the surface of leukocytes. We report the unexpected discovery 
that certain GBS strains may bind one such receptor, hSiglec-5, in a Sia-independent man-
ner, via the cell wall–anchored  protein, resulting in recruitment of SHP protein tyrosine 
phosphatases. Using a panel of WT and mutant GBS strains together with Siglec-expressing 
cells and soluble Siglec-Fc chimeras, we show that GBS  protein binding to Siglec-5  
functions to impair human leukocyte phagocytosis, oxidative burst, and extracellular trap 
production, promoting bacterial survival. We conclude that protein-mediated functional 
engagement of an inhibitory host lectin receptor promotes bacterial innate immune evasion.
© 2009 Carlin et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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and probed with hSiglec-Fc chimeras and secondary anti–
human HRP-conjugated antibodies. The hSiglec-5-Fc chi-
mera interacted with a GBS protein of an apparent molecular 
mass of 125 kD found in lysates of the GBS serotype Ia strain 
but not in the serotype III control (Fig. 1 C). The hSiglec-
9-Fc chimera did not interact with this protein or any   
others, excluding nonspecific interactions with the human 
IgG-Fc portion of the chimeras. Based on size, surface location, 
sensitivity to trypsin, presence in the GBS serotype Ia strain, 
and absence in the GBS serotype III strain, we hypothesized 
that the protein mediating GBS interaction with hSiglec-5-Fc 
was the surface-expressed  protein (also known as Bac or 
C; Lindahl et al., 2005). To produce a partially purified 
GBS  protein extract, we incubated the GBS serotype Ia and 
serotype III (negative control) NeuA mutants at pH 9.7 for 
4 h at 37°C, selectively releasing  protein (Lindahl et al., 
1990), concentrated and separated supernatants by SDS-PAGE, 
and then blotted and probed with hSiglec-5-Fc. This sample 
was highly enriched for the 125-kD protein interacting with 
hSiglec-5-Fc (Fig. 1 D). Treatment of the protein extract 
with active or heat-inactivated (control) Arthrobacter ureafa-
ciens sialidase (AUS) did not change hSiglec-5-Fc binding 
(Fig. 1 E). To determine the identity of the 125-kD GBS 
protein, the band reacting with hSiglec-5-Fc was excised, 
digested, and analyzed using MALDI-TOF MS peptide fin-
gerprinting (Fig. S1 B). The monoisotopic masses of the 
peptide fragments listed were analyzed using the online 
database at Rockefeller University (http://prowl.rockefeller 
.edu) and the GBS  protein was identified with 100% cer-
tainty. Confirming the significance of the observed interac-
tion, an isogenic  protein–deficient mutant (Bac) of our 
parent GBS Ia strain lost the ability to bind hSiglec-5-Fc, but 
when it was complemented with the bac gene expressed on 
a plasmid vector (pBac), WT levels of hSiglec-5-Fc binding 
were restored (Fig. 1 F).
The  protein is required for GBS interactions with  
hSiglec-5 via its N-terminal domain
The GBS  protein N-terminal (cell wall distal) domain   
is known to bind human IgA-Fc, whereas its C-terminal   
domain can interact with human factor H (Areschoug et al., 
2002). To map the domain for  protein–hSiglec-5 interac-
tion, we preincubated GBS with or without polyclonal anti-
bodies against full-length  protein (Beta Ab), its N-terminal 
domain (B6 Ab), or its C-terminal domain (75 kD antibody; 
Fig. 2 A). The Beta Ab and B6 Ab significantly blocked GBS 
binding  to  hSiglec-5-Fc,  causing  >75%  (P  <  0.001)  and 
>95% (P < 0.001) inhibition, respectively (Fig. 2 B). In con-
trast, the 75-kD Ab did not interfere with GBS hSiglec-5-Fc 
binding (Fig. 2 B). Immunoblot confirmed that the N-termi-
nal B6 domain, but not the 75-kD C-terminal fragment, bound 
hSiglec-5-Fc (Fig. 2 C). Note that recombinant B6 protein is 
size heterogeneous (Heden et al., 1991). Furthermore, GBS  
protein bound hSiglec-5 and baboon Siglec-5, but not chim-
panzee Siglec 5 (Fig. S2), mapping  protein binding to the 
hSiglec-5 V-set (lectin) domain because this domain contains 
whereas the distal motif (TEYSEI) resembles the immuno-
receptor tyrosine–based switch motif (TXYXX[V/I]) found in 
the CD150/SLAM subfamily (Ravetch and Lanier, 2000). 
The immunoreceptor tyrosine–based inhibitory motif is pres-
ent in various inhibitory receptors that antagonize kinase-
  dependent activation cascades (Taylor et al., 2000) and function 
by recruiting Src homology 2 domain–containing tyrosine 
phosphatases SHP-1 (Zhang et al., 2000) and SHP-2 (Gergely 
et al., 1999). Both hSiglec-5 and hSiglec-9 can recruit SHP-1 
and SHP-2 and function as inhibitory receptors of leukocytes 
(Avril et al., 2006a).
We recently demonstrated that GBS of different serotypes 
bind hCD33rSiglecs (Carlin et al., 2007) and that GBS sero-
type III engages Siglec-9 on the surface of cells, including 
human neutrophils, in a Sia- and Siglec-specific manner to 
down-regulate their immune responsiveness (Carlin et al., 
2009). In this paper, we report the unexpected discovery that 
certain  GBS  strains  bind  hSiglec-5  in  a  Sia-independent   
manner, via a specific protein anchored to the bacterial cell 
wall. Using a combination of bacterial and immunological 
reagents, we characterize the protein-mediated interaction of 
GBS with Siglec-5 on the surface of human leukocytes and 
present functional evidence that it represents a novel bacterial 
immune evasion mechanism.
RESULTS AND DISCUSSION
GBS interacts with hSiglec-5-Fc through a trypsin-sensitive 
bacterial protein
We tested WT GBS isolates expressing sialylated CPS of se-
rotypes Ia (strain A909) and III (strain COH1), isogenic Sia-
negative mutants of each strain generated by allelic replacement 
of the CMP-Neu5Ac-synthase gene (NeuA), and GBS 
pretreated with trypsin to remove cell surface proteins, for 
binding to chimeras of hSiglec5 (hSiglec-5-Fc) and hSiglec-9 
(hSiglec-9-Fc) by flow cytometry. Corroborating our previ-
ous ELISA-based findings (Carlin et al., 2007), serotype III 
GBS bound to hSiglec-9-Fc and serotype Ia bound to hSiglec-5 
(Fig. 1, A and B). The GBS serotype III strain bound to 
hSiglec-9-Fc in a Sia-specific manner because this interaction 
was lost for the isogenic Sia-negative NeuA mutant but un-
altered by trypsin treatment (Fig. 1 A). In contrast, attachment 
of the GBS serotype Ia strain to hSiglec-5-Fc was maintained 
in the Sia-deficient mutant and eliminated by trypsin treat-
ment (Fig. 1 B), linking binding to a trypsin-sensitive protein 
rather than the anticipated sugar–lectin interaction.
The GBS  protein interacts with hSiglec-5 in a Sia-
independent manner
To identify the proteins responsible for mediating attach-
ment to hSiglec-5, we prepared whole cell lysates of the 
GBS serotype Ia strain that bound hSiglec-5-Fc and, as a 
control, the nonbinding GBS serotype III strain. To avoid 
hSiglec-Fc Sia-specific interactions, isogenic NeuA mu-
tants that were virtually devoid of detectable cell surface Sia 
(Fig. S1 A) were used. Proteins were separated under reduc-
ing conditions by SDS-PAGE, transferred to a PVDF filter, JEM VOL. 206, August 3, 2009  1693
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complementation with the pBac plasmid (Fig. 2 D). GBS attach-
ment to transfected CHO cells was dependent on hSiglec-5, as 
anti–Siglec-5 antibody significantly blocked the binding (Fig. 2 
D). Adherence was quantified by lifting the monolayers and 
analyzing single cells for adherent FITC-GBS by flow cytom-
etry (Fig. 2 E). Adherent WT GBS or pBac-complemented 
Bac mutant were present on the majority of cells, usually with 
more than one attached FITC-labeled bacterium per cell (greater 
shifts in fluorescence intensity). In contrast, very few Bac mu-
tant bacteria adhered to the CHO(hSiglec5) cells. Anti–Siglec-5 
antibody reduced WT GBS binding to the level observed with 
the Bac mutant (Fig. 2 E). We conclude that binding of GBS 
to the cell surface is a direct result of  protein–mediated bind-
ing to hSiglec-5.
all amino acid residues in chimpanzee Siglec-5 that differ from 
the hSiglec5 sequence but are not shared by baboon Siglec-5.
GBS binding to cell surface–expressed hSiglec-5  
is  protein dependent
To determine if GBS  protein could bind hSiglec-5 on a   
eukaryotic cell surface, we stably transfected CHO-K1 cells with 
an  hSiglec-5  expression  plasmid  and  applied  FITC-labeled 
GBS to the monolayers. Nonadherent bacteria were washed 
away and fluorescent images of adherent GBS captured. WT 
GBS expressing  protein adhered to CHO cells expressing 
hSiglec-5 (Fig. 2 D) but not to nontransfected cells (not de-
picted). In contrast, the Bac mutant did not adhere to CHO 
cells expressing hSiglec5, and binding was restored upon mutant 
Figure 1.  The GBS  protein mediates attachment to hSiglec-5-Fc in a Sia-independent manner. (A and B) WT GBS serotype III (A) and Ia (B) and 
their isogenic Sia-deficient NeuA mutants were incubated with hSiglec-9-Fc and hSiglec-5-Fc, respectively, followed by PE-conjugated secondary  
antibodies, and analyzed by flow cytometry for Sia-dependent binding of hSiglecs. Similar analysis was performed with WT GBS serotype III (A) and Ia 
(B) pretreated with or without trypsin to determine protein-dependent binding of hSiglecs. (C) Western blot analysis of GBS whole cell lysates from GBS 
serotype Ia and III NeuA mutants with hSiglec-Fc chimeras as probes. The analysis identified an 125-kD specific hSiglec-5 binding protein in the Ia strain.  
(D) Analysis of GBS extracts prepared under basic conditions (pH 9.7) also identified an 125-kD protein that binds hSiglec5. (E) AUS treatment (50 mU/ml 
for 2 h) does not affect binding of the 125-kD protein to hSiglec5. (F) WT GBS serotype Ia and isogenic mutant Bac (lacking the  protein), or the plasmid 
complemented mutant Bac + pBac, were incubated with hSiglec-5-Fc and PE-conjugated secondary antibody and analyzed by flow cytometry. All experi-
ments were performed in duplicate and repeated three (A and B) or four (C–F) times with similar results. Representative experiments are shown.1694 GBS BINDS SIGLEC-5 TO INHIBIT PHAGOCYTES | Carlin et al.
Bac mutant to U937 monocytes (Fig. 3 B, P = 0.01) and 
human neutrophils (Fig. 3 C, P < 0.001). To correlate bind-
ing to phagocytic uptake, we incubated bacteria with U937 
monocytes for 30 min at 37°C, killed extracellular bacteria 
using antibiotics, and lysed monocytes to recover internalized 
bacteria  for  enumeration.  U937  cells  phagocytosed  more 
Bac mutant bacteria than either the WT GBS parent strain 
or the complemented mutant (Fig. 3 D, P < 0.001). Antibody 
cross-linking of Siglec-5 causes rapid endocytosis of the recep-
tor so that only 5–10% remains on the cell surface after 45 
min (unpublished data). Upon depletion of hSiglec-5 from the 
U937 cell surface using an anti–hSiglec-5 antibody, phagocy-
tosis of WT GBS approached the levels seen with the isogenic 
Bac mutant (Fig. 3 D). Thus, although GBSs expressing  
protein bind to human leukocytes more avidly, they are 
phagocytosed less efficiently, and this reduction depends on 
cell surface expression of hSiglec-5. Additional differential fluo-
rescence studies to quantify phagocytosed versus extracellular 
GBSs expressing  protein colocalize with hSiglec-5  
on the surface of human monocytes
GBS–U937 monocyte interactions were visualized using fluo-
rescent deconvolution microscopy with a hSiglec-5–specific 
antibody, a fluorescently tagged (red) secondary antibody to 
label hSiglec-5, and Hoechst DNA stain (blue) to visualize 
cell nuclei. WT GBS expressing  protein colocalized with 
clear aggregations of hSiglec-5 present on the U937 cell sur-
face (Fig. 3 A). Increased quantities of hSiglec-5 at the inter-
face of the Bac mutant and the U937 cell surface were not 
observed; consequently, the Manders coefficient for colocal-
ization of bacteria and hSiglec-5 was significantly less in the 
Bac mutant compared with the WT GBS strain (Fig. 3 A).
 protein binding to Siglec-5 promotes GBS leukocyte 
attachment but impairs phagocytosis
In a binding experiment at 4°C to prevent phagocytosis, the 
WT GBS strain bound to a greater degree than did the isogenic 
Figure 2.  The N-terminal domain of the  protein mediates hSiglec-5–Fc interactions and can promote GBS binding to CHO cells express-
ing hSiglec-5. (A) Schematic of the GBS  protein, including the peptide fragments previously used to generate rabbit polyclonal antisera Beta, B6, and 
75 kD. (B) WT GBS were preincubated with rabbit polyclonal antisera targeting various domains of the  protein before addition of hSiglec-5-Fc, 
and analysis of hSiglec-5-Fc binding by flow cytometry. (C) Western blot analysis shows direct binding of Siglec-5 to the B6 region of the  protein. 
(D) FITC-labeled GBS were allowed to adhere to CHO cells transfected with hSiglec-5 for 20 min and nonadherent GBS were removed by repeated washing.  
In blocking experiments, CHO cells were preincubated with anti–Siglec-5 antibody for 10 min. Bar, 100 µm. (E) To quantify GBS attachment to individual 
cells, CHO cell monolayers were lifted with PBS + 5 mM EDTA and analyzed by flow cytometry. All experiments repeated three (B, D, and E) or two  
(C) times with similar results. Images show pooled data (B and E) or a representative experiment (C and D). Error bars represent standard deviation. 
Statistical analysis was performed using one-way ANOVA with Tukey’s post-test.JEM VOL. 206, August 3, 2009  1695
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CHO(hSiglec-5) cells were exposed to WT GBS, SHP-2 was 
recruited to hSiglec-5 beginning at 5 min and reached a 
maximum at 15–20 min (Fig. 4 A). In contrast, no recruitment 
of SHP-2 to hSiglec-5 on CHO(hSiglec-5) was detected after 
exposure to the GBS Bac mutant. Similarly, U937 monocytes, 
which had no detectable SHP-2 associated with hSiglec-5 at 
baseline, showed recruitment of SHP-2 in response to WT GBS 
but not the Bac mutant (Fig. 4 B). Recruitment of SHP-1 to 
Siglec 5 in U937 monocytes did not differ appreciably after 
exposure to the WT and Bac strain (Fig. 4 B); however, when 
 protein was expressed heterologously in a Sia-deficient acap-
sular strain of Lactococcus lactis, a contribution of the protein to 
recruitment of both SHP-2 and SHP-1 to hSiglec-5 could be 
detected (Fig. 4 B). The observed GBS  protein–dependent 
SHP-2 recruitment to Siglec-5 resembles Sia-dependent   
adherent bacteria corroborate these observations (Fig. S3, A 
and B). A similar inhibitory effect of GBS  protein expression 
on U937 cell phagocytosis was observed in serum-free assays, 
excluding any theoretical confounding effect of the  protein 
binding to IgA (Fig. S3 C).
 protein expression can increase SHP recruitment  
to hSiglec-5
CD33rSiglecs mediate inhibitory signaling in immune cells via 
recruitment of SHP protein tyrosine phosphatases. We incu-
bated the WT GBS strain and Bac mutant with CHO cells 
expressing hSiglec-5, performed immunoprecipitation for   
hSiglec-5, and then probed for coimmunoprecipitation of   
tyrosine phosphatase SHP-2. SHP-2 was not recruited to 
hSiglec-5 in the absence of bacteria (Fig. 4 A). However, when 
Figure 3.  GBS expressing  protein colocalize with hSiglec-5 on U937 leukocytes and neutrophils, increasing bacterial attachment but 
impairing their phagocytosis (A) Colocalization of FITC-WT GBS (green) with hSiglec 5 (red) on the cell surface of U937 cells (blue nuclei) 
not observed in parallel studies with the isogenic FITC-labeled  protein–deficient mutant, as visualized by deconvolution microscopy. Bar, 
5 µm. (B) FITC-labeled GBS were allowed to interact with U937 for 60 min at 4°C (to prevent phagocytosis). Adherence was measured by flow cytometry.  
(C) Primary human neutrophils were incubated with live GBS-FITC on ice to allow cell–cell interactions but block phagocytosis. The percentage of neutro-
phils with adherent bacteria was measured using flow cytometry. (D) To calculate phagocytic uptake of GBS, bacteria were added to U937 at MOI 10:1 for 
30 min, washed, antibiotics added for 2 h to kill extracellular bacteria, and then cells lysed and dilutions plated to enumerate intracellular CFU. Where 
indicated, U937 cells were preincubated with anti–Siglec-5 Ab (1-A5) for 50 min, which results in endocytosis of the receptor, leaving 10% of original 
levels of Siglec-5 on the surface before addition of GBS. Horizontal bars represent the mean. Each experiment was performed in triplicate and repeated 
three times with similar results. Representative images (A) or pooled data (Manders coefficient; B–D) are shown. Error bars represent standard deviation. 
Statistical analysis was performed using one-way ANOVA with Tukey’s post-test.1696 GBS BINDS SIGLEC-5 TO INHIBIT PHAGOCYTES | Carlin et al.
engagement of hSiglec-5 with an anti–hSiglec-5 monoclonal 
antibody increased neutrophil killing of GBS (Fig. 5 E). These 
findings indicated that  protein–expressing GBS strains can 
use this protein to suppress the innate immune function of 
phagocytic cells.
Protein-mediated Siglec engagement and GBS  
immune evasion
The  protein is the first example of a protein other than an 
antibody that directly engages the extracellular domains of an 
hCD33rSiglec in a Sia-independent manner. Previously, GBS 
and two other human pathogens, Neisseria meningitidis and 
Campylobacter jejuni, were shown to interact with hCD33r- 
Siglecs through cell surface–expressed Sia (Jones et al., 2003; 
Avril et al., 2006b; Carlin et al., 2007) and, in the case of GBS, 
these Sia-dependent interactions served to down-regulate 
neutrophil activation (Carlin et al., 2007). GBS association 
with hSiglec-5 in a protein-dependent manner reveals a novel 
mechanism by which pathogens may co-opt hCD33rSiglecs 
to their advantage.  protein–mediated engagement causes an 
accumulation of Siglec-5 at the sight of GBS contact and in-
creases the recruitment of SHP protein tyrosine phosphatases 
to  the  receptor’s  cytosolic  tail.  Association  of  SHP  family 
phosphatases with surface receptors can negatively regulate 
receptor-mediated phagocytosis (Oldenborg et al., 2001; Kant 
et al., 2002). Likewise, the antiphagocytic effect described in 
this  paper  is  mediated  by    protein–expressing  GBS  only 
when Siglec-5 is present on the leukocyte surface and, thus, 
likely depends on SHP recruitment to the surface receptor.
The GBS  protein is a large antigenic surface-anchored 
protein expressed in almost all GBS serotype Ib strains and 
some serotype Ia, II, and V strains but almost never in sero-
type III strains (Lindahl et al., 2005). Recently, it was shown 
that high levels of  protein expression are associated with in-
creased virulence of GBS clinical isolates (Nagano et al., 2002). 
 protein is known to interact with two components of the 
human immune system, the Fc portion of serum IgA and 
factor H (Areschoug et al., 2002), and our present finding that 
 protein binds to hSiglec-5 identifies a third such interaction. 
Through nonimmune binding of IgA (Pleass et al., 2001),   
engagement of factor H (a major regulator of complement; 
Pangburn, 2000), and, now, attachment to hSiglec5, which is 
proposed to play an important role in regulating phagocyte 
function and the link to cellular immunity (Crocker et al., 
2007),  protein appears to be a multifunctional virulence 
factor capable of interfering with several aspects of host defense 
to bacterial infection.
We have shown that GBS is able to engage different 
CD33rSiglecs using its sialylated CPS or the  protein. The 
Sia-binding sites of hCD33rSiglecs are rapidly evolving, a 
process that is hypothesized to be likely to facilitate continual 
host Sia self-recognition in the face of rapid changes in host 
Sia expression (Varki and Angata, 2006). In this scenario, rapid 
evolution of the host sialome, driven by Sia-binding patho-
gens such as malaria and influenza, requires that the CD33r-
Siglecs also evolve rapidly to keep up with recognizing self. 
recruitment of SHP-2 to hSiglec9 in U937 cells exposed to   
serotype III GBS (Fig. S4).
 protein interferes with neutrophil activation and  
killing of GBS
Recently, we reported that GBS serotype III mimicry of host 
Sias allowed engagement of hSiglec-9, leading to reduced 
neutrophil phagocytosis, diminished oxidative burst, and im-
paired formation of neutrophil extracellular traps (NETs; 
Brinkmann et al., 2004), together promoting pathogen sur-
vival (Carlin et al., 2007). In this study, we performed addi-
tional neutrophil studies to ascertain how the newly discovered 
GBS  protein–mediated engagement of hSiglec-5 would af-
fect these phagocyte functions. Compared with the isogenic 
Bac mutant, the WT GBS strain elicited a weaker oxidative 
burst (Fig. 5 A), triggered the release of fewer NETs (Fig. 5 B), 
and stimulated less transcription of IL-8 (Fig. 5 C) upon co-
incubation with human neutrophils. Moreover, the WT GBS 
strain showed increased survival versus the Bac mutant in a 
neutrophil killing assay (Fig. 5 D). Inhibition of  protein 
Figure 4.  GBS  protein effects on recruitment of SHP family 
protein tyrosine phosphatases to hSiglec-5. (A) SHP-2 recruitment to 
hSiglec-5 by coimmunoprecipitation studies in CHO cells transfected with 
hSiglec-5 and exposed to WT and  protein–deficient GBS. (B) SHP-1 and 
SHP-2 recruitment to hSiglec-5 by coimmunoprecipitation studies in 
human U937 monocytes exposed to WT and  protein–deficient GBS or  
L. lactis expressing the GBS  protein or empty vector control. *N-glycans 
were removed using PNGase F before separation by SDS-PAGE in CHO cell 
experiments. All experiments performed three times with similar results.  
A representative experiment is shown.JEM VOL. 206, August 3, 2009  1697
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microorganisms and, thus, may represent a more widespread 
strategy of microbial immune evasion.
Materials and Methods
Bacteria, growth conditions, and labeling. GBS WT strains of serotypes 
Ia (A909) and III (COH1) are well-characterized isolates from human neo-
nates with invasive infections. Generation of the NeuA and Bac mutants 
and complemented mutants of A909 and COH1 have been previously   
reported (Areschoug et al., 2002; Lewis et al., 2004, 2007). GBS were grown 
and prepared for assays including sialidase and trypsin treatment as previously 
described (Carlin et al., 2007). Live GBS were incubated in PBS + 0.1% 
FITC (Sigma-Aldrich) at 37°C for 20 min; alternatively, heat-killed GBS 
were labeled as previously described (Carlin et al., 2007).
Siglec-Fc binding assays. hSiglec-Fc chimeras were produced as previ-
ously described (Angata and Varki, 2000). GBSs were resuspended in RPMI + 
10% FCS at 4oC with 10 µg/ml hSiglec-Fc, fluorescent secondary Ab, and 
analyzed by flow cytometry. In blocking experiments, GBS were preincubated 
If GBS CPS Sias have evolved to engage inhibitory CD33r-
Siglecs, then these Sias would need to coevolve with the rapidly 
changing Sia-binding specificities of CD33rSiglecs to main-
tain functional interactions. The parallel evolution by GBS   
of a protein ligand that allows functional engagement of 
hSiglec-5 may have facilitated continued success of CPS sero-
types (e.g., type Ia) that had lost their original binding affinity 
to host Siglec-5.
In  sum,  we  demonstrate  the  presence  of  a  microbial   
protein ligand that engages a member of the hCD33rSiglecs 
and find that this interaction increases bacterial resistance to 
phagocytosis and killing by human leukocytes. Recent studies 
suggest that Sia-expressing pathogenic microorganisms may 
use cell surface Sias to bind hCD33rSiglecs to dampen innate 
immune responses. Our present findings indicate that this 
pathogenic mechanism may not be limited to Sia-expressing 
Figure 5.  GBS  protein effects on human neutrophil activation and killing. (A) Oxidative burst activity of neutrophils exposed to GBS WT, Bac 
mutant, and complemented mutant strains. (B) Production of NETs in response to GBS WT, Bac mutant, and complemented mutant strains. Bar, 50 µm. 
(C) Comparison of WT and Bac mutant GBS strains in induction of IL-8 transcript from human neutrophils. (D and E) Survival of GBS WT and Bac  
mutant strains upon coincubation with human neutrophils (D), with or without coincubation with anti–Siglec-5 Ab or control Ab (E). All experiments 
performed in triplicate and repeated three (A–C and E) or two (D) times with similar results. A representative experiment (A, C, and D) or pooled data  
(B and E) are shown. The error bars represent mean value ± SD.1698 GBS BINDS SIGLEC-5 TO INHIBIT PHAGOCYTES | Carlin et al.
IgG1 control (Sigma-Aldrich) Ab was added to purified neutrophils 2 min   
before the assay. Protocols were approved by the University of California, San 
Diego Human Research Protection Program.
Online supplemental material. Fig. S1 shows analysis of GBS surface 
Sia  expression  and  mass  spectrometric  identification  of  GBS    protein. 
Fig. S2 shows that GBS-expressing  protein binds to human and baboon 
  Siglec-5 but not chimpanzee Siglec-5. Fig. S3 corroborates that GBS  
protein impairs human monocyte phagocytosis in an hSiglec-5–dependent 
manner and under serum-free conditions. Fig. S4 shows that GBS sero-
type III Sia promotes recruitment of SHP-2 protein tyrosine phosphatases 
to hSiglec-9. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090691/DC1.
We would like to thank Kersi Pestonjamasp for work with the University of California, 
San Diego (UCSD) Cancer Center Digital Imaging Shared Resource, Colin McGinn for 
assistance with the Visualization Portal at the UCSD Supercomputer Center, and Paul 
Crocker for providing the anti–Siglec-5 antibody (1A5) supernatants.
This work was supported by National Institutes of Health awards R01-
HD051796 (V. Nizet) and P01-HL57345 (A. Varki), an American Heart Association 
Established Investigator Award (V. Nizet), and a grant from the Swedish Research 
Council (G. Lindahl).
The authors have no conflicting financial interests.
submitted: 27 March 2009
accepted: 19 June 2009
REFERENCES
Angata, T., and A. Varki. 2000. Cloning, characterization, and phylogenetic 
analysis of siglec-9, a new member of the CD33-related group of siglecs. 
Evidence for co-evolution with sialic acid synthesis pathways. J. Biol. Chem. 
275:22127–22135. 
Areschoug, T., M. Stalhammar-Carlemalm, I. Karlsson, and G. Lindahl. 
2002. Streptococcal  protein has separate binding sites for human factor 
H and IgA–Fc. J. Biol. Chem. 277:12642–12648. 
Avril, T., H. Attrill, J. Zhang, A. Raper, and P.R. Crocker. 2006a. Negative 
regulation of leucocyte functions by CD33-related siglecs. Biochem. Soc. 
Trans. 34:1024–1027. 
Avril, T., E.R. Wagner, H.J. Willison, and P.R. Crocker. 2006b. Sialic 
acid-binding immunoglobulin-like lectin 7 mediates selective recognition 
of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. 
Infect. Immun. 74:4133–4141. 
Brinkmann, V., U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D.S. 
Weiss, Y. Weinrauch, and A. Zychlinsky. 2004. Neutrophil extracellular 
traps kill bacteria. Science. 303:1532–1535. 
Carlin, A.F., A.L. Lewis, A. Varki, and V. Nizet. 2007. Group B streptococcal 
capsular sialic acids interact with siglecs (immunoglobulin-like lectins) 
on human leukocytes. J. Bacteriol. 189:1231–1237. 
Carlin, A.F., S. Uchiyama, Y.C. Chang, A.L. Lewis, V. Nizet, and A. Varki. 
2009. Molecular mimicry of host sialylated glycans allows a bacterial 
pathogen to engage neutrophil Siglec-9 and dampen the innate immune 
response. Blood. 113:3333–3336. 
Crocker, P.R., J.C. Paulson, and A. Varki. 2007. Siglecs and their roles in 
the immune system. Nat. Rev. Immunol. 7:255–266. 
Dermer, P., C. Lee, J. Eggert, and B. Few. 2004. A history of neonatal group   
B streptococcus with its related morbidity and mortality rates in the United 
States. J. Pediatr. Nurs. 19:357–363. 
Gergely, J., I. Pecht, and G. Sarmay. 1999. Immunoreceptor tyrosine-based 
inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-
based activation motif-induced activation of immune competent cells. 
Immunol. Lett. 68:3–15. 
Heden, L.O., E. Frithz, and G. Lindahl. 1991. Molecular characterization of an 
IgA receptor from group B streptococci: sequence of the gene, identification 
of a proline-rich region with unique structure and isolation of N-terminal 
fragments with IgA-binding capacity. Eur. J. Immunol. 21:1481–1490. 
Jones, C., M. Virji, and P.R. Crocker. 2003. Recognition of sialylated   
meningococcal lipopolysaccharide by Siglecs expressed on myeloid cells 
leads to enhanced bacterial uptake. Mol. Microbiol. 49:1213–1225. 
with polyclonal rabbit anti– protein antibodies (Beta antibody, B6, or   
75 kD; Heden et al., 1991; Areschoug et al., 2002) for 20 min at 4oC.
GBS protein isolation, purification, and Western blots. GBS were 
washed and disrupted in lysis buffer with multiple freeze-thaw cycles, and 
extracts were centrifuged at 4°C. Supernatants were concentrated with Ami-
con Ultra-10 (Millipore), separated by SDS-PAGE under reducing condi-
tions,  and  either  stained  with  GelCode  blue  (Thermo  Fisher  Scientific)   
or transferred to PVDF, blocked, probed with 5 µg/ml Siglec-Fc chimeras 
and HRP-conjugated secondary Ab, and then detected with ECL reagent 
(Thermo Fisher Scientific). Partial purification of the  protein was performed 
with slight modifications as previously described (Stalhammar-Carlemalm   
et al., 1993). GBS were incubated in 50 mM Tris, pH 9.7, at 37°C and 
supernatants concentrated with Microcon 30 (Millipore), separated, and 
probed with Siglec-Fc chimeras.
Mammalian protein isolation and Western blots. Cells were infected 
with GBS, washed, and lysed with 4°C TBS lysis buffer. Protein concentra-
tions were normalized and immunoprecipitation was performed with 1A5 
anti–human Siglec-5 antibody (gift from P. Crocker, University of Dundee, 
Dundee, Scotland, UK) and protein G Sepharose beads (4 fast flow; BD). 
Proteins were separated by reducing SDS-PAGE, transferred to PVDF, and 
probed with anti–Siglec-5 antibody BAF1072 (R&D systems), rabbit anti–
SHP-1 (Santa Cruz Biotechnology, Inc.), or rabbit anti–SHP-2 (Millipore) 
and appropriate HRP-conjugated secondary Abs (Bio-Rad Laboratories) and 
ECL reagent (Thermo Fisher Scientific). U937 cells were resuspended in 
RPMI + 0.5% FCS overnight before assays. For assays using CHO cells,   
N-glycans were removed using PNGase F before separation by SDS-PAGE.
GBS adherence and phagocytosis assays. CHO cell adherence assays 
were performed as described previously (Carlin et al., 2007). FITC-GBS 
were added to human leukocytes at 4°C in RPMI + 10% FCS, centrifuged 
to initiate contact, and rotated at 4°C for 30 min before analysis of adherence 
by flow cytometry. Phagocytosis assays were performed with or without 
preincubation in heat-inactivated human serum (HIHS). GBS MOI 10:1 
were added to U937 cells and incubated at 37°C for 30 min before adding 
5 µg/ml of penicillin and 100 µg/ml of gentamicin for 2 h to kill extracellular 
bacteria. Cells were washed and lysed and intracellular bacteria were enu-
merated using serial dilution plating. In specific assays, U937 cells were de-
pleted of cell surface Siglec-5 by preincubation with 2 µl/ml of anti–Siglec-5 
1A5 Ab for 50 min at 37°C in RPMI before adding GBS.
GBS U937 cell deconvolution microscopy. Live FITC-GBS were added 
to U937 cells in HBSS MOI 5:1, incubated at 37°C for 10 min, washed, and 
resuspended in ice cold PBS + 1% BSA. Siglec-5 was labeled with 1A5 Ab and 
Alexa Fluor 647–conjugated secondary Ab (Invitrogen). Cells were fixed in 
2% paraformaldehyde, spun onto poly-lysine–coated coverslips, and mounted 
in Prolong Gold with DAPI (Invitrogen). At least five images of GBS interac-
tions were captured from three independent experiments as previously de-
scribed (Carlin et al., 2007). Image Pro Plus software was used to determine 
Manders coefficients for green (GBS) colocalization with red (hSiglec-5) for 
every bacterial–cell interaction captured. The mean ± SEM of WT and Bac 
GBS were graphed and P-value was determined by a Student’s t test.
Neutrophil functional assays. Human neutrophils were prepared as previ-
ously described (Carlin et al., 2007) using Polymorphprep solution (Axis-
Shield PoC AS) according to the manufacturer’s instructions. Experiments 
were performed as previously described (Carlin et al. 2009) with minor modi-
fications. IL-8 transcript was assessed by quantitative real-time RT-PCR. GBS 
were incubated in HBSS + 10% HIHS for 20 min at 37°C and added to neu-
trophils at MOI of 10:1 in HBSS + 2% HIHS final concentration and incu-
bated for 10 min (oxidative burst) or 30 min (NETs) before analysis. GBS were 
added and the bacteria and neutrophils were spun together at 500 g for 5 min 
to initiate the assay. For neutrophil killing assays performed in the presence of 
antibodies, 5 µg/ml of anti–Siglec-5 Ab (clone 194128; R&D Systems) or JEM VOL. 206, August 3, 2009  1699
BRIEF DEFINITIVE REPORT
Kant, A.M., P. De, X. Peng, T. Yi, D.J. Rawlings, J.S. Kim, and D.L. 
Durden. 2002. SHP-1 regulates Fc receptor-mediated phagocytosis 
and the activation of RAC. Blood. 100:1852–1859.
Lewis, A.L., V. Nizet, and A. Varki. 2004. Discovery and characterization 
of sialic acid O–acetylation in group B Streptococcus. Proc. Natl. Acad. Sci. 
USA. 101:11123–11128. 
Lewis, A.L., S.K. Patel, S. Diaz, W. Ryan, H. Cao, A.F. Carlin, V. Thon, 
W.G. Lewis, A. Varki, X. Chen, and V. Nizet. 2007. NeuA O-acetyles-
terase activity modulates O-acetylation of capsular sialic acids in group B 
Streptococcus. J. Biol. Chem. 282:27562–27571.
Lindahl,  G.,  B.  Akerstrom,  J.P.  Vaerman,  and  L.  Stenberg.  1990. 
Characterization of an IgA receptor from group B streptococci: speci-
ficity for serum IgA. Eur. J. Immunol. 20:2241–2247. 
Lindahl, G., M. Stalhammar-Carlemalm, and T. Areschoug. 2005. Surface 
proteins of Streptococcus agalactiae and related proteins in other bacterial 
pathogens. Clin. Microbiol. Rev. 18:102–127. 
Marques, M.B., D.L. Kasper, M.K. Pangburn, and M.R. Wessels. 1992. 
Prevention of C3 deposition by capsular polysaccharide is a viru-
lence mechanism of type III group B streptococci. Infect. Immun. 
60:3986–3993.
Nagano, N., Y. Nagano, and F. Taguchi. 2002. High expression of a C protein 
 antigen gene among invasive strains from certain clonally related groups 
of type Ia and Ib group B streptococci. Infect. Immun. 70:4643–4649. 
Oldenborg, P.A., H.D. Gresham, and F.P. Lindberg. 2001. CD47-signal regula-
tory protein  (SIRP) regulates Fc and complement receptor–mediated 
phagocytosis. J. Exp. Med. 193:855–862. 
Pangburn, M.K. 2000. Host recognition and target differentiation by factor H, 
a regulator of the alternative pathway of complement. Immunopharmacology. 
49:149–157. 
Paoletti, L.C., and D.L. Kasper. 2003. Glycoconjugate vaccines to prevent 
group B streptococcal infections. Expert Opin. Biol. Ther. 3:975–984. 
Pleass, R.J., T. Areschoug, G. Lindahl, and J.M. Woof. 2001. Streptococcal 
IgA-binding proteins bind in the C2-C3 interdomain region and 
inhibit binding of IgA to human CD89. J. Biol. Chem. 276:8197–8204. 
Ravetch, J.V., and L.L. Lanier. 2000. Immune inhibitory receptors. Science. 
290:84–89. 
Stalhammar-Carlemalm, M., L. Stenberg, and G. Lindahl. 1993. Protein rib: 
a novel group B streptococcal cell surface protein that confers protective 
immunity and is expressed by most strains causing invasive infections. 
J. Exp. Med. 177:1593–1603. 
Taylor, L.S., S.P. Paul, and D.W. Mcvicar. 2000. Paired inhibitory and   
activating receptor signals. Rev. Immunogenet. 2:204–219.
Varki, A. 2007. Glycan-based interactions involving vertebrate sialic-
acid-recognizing proteins. Nature. 446:1023–1029. 
Varki, A., and T. Angata. 2006. Siglecs–the major subfamily of I-type lectins. 
Glycobiology. 16:1R–27R. 
Wessels, M.R., C.E. Rubens, V.J. Benedi, and D.L. Kasper. 1989. Definition 
of a bacterial virulence factor: sialylation of the group B streptococcal 
capsule. Proc. Natl. Acad. Sci. USA. 86:8983–8987. 
Zhang, J., A.K. Somani, and K.A. Siminovitch. 2000. Roles of the SHP-1 
tyrosine phosphatase in the negative regulation of cell signalling. Semin. 
Immunol. 12:361–378. 